Tau Antibody Therapy in Neurodegenerative Diseases

Tau vaccination and administration of anti-tau antibodies can prevent pathology and cognitive impairment in transgenic mouse models of tauopathy, suggesting that therapies which increase anti-tau antibodies might slow the development and/or progression of tauopathies including Alzheimer's disease. Here is the latest research.

September 13, 2020

Downregulation of G3BP2 reduces atherosclerotic lesions in ApoE-/- mice

Atherosclerosis
Tianhan LiGuixue Wang
September 10, 2020

Novel Monoclonal Antibodies Targeting the RRM2 domain of Human TDP-43 Protein

Neuroscience Letters
Jorge A Trejo-LopezBenoit I Giasson
August 12, 2020

Preparation and in vitro activity of single chain antibodies against Alzheimer's disease

Immunology Letters
Lu FuLinbo Zhang
August 13, 2020
Open Access

Peri-arterial pathways for clearance of α-Synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring
Jacqui NimmoRoxana O Carare
July 10, 2020
Review
Open Access

Understanding cause and effect in Alzheimer's pathophysiology: implications for clinical trials

Neuropathology and Applied Neurobiology
Delphine Boche, James A R Nicoll
September 5, 2020

Decoding the Inter-relationship between Sleep Disorders and Alzheimer's disease Pathogenesis

CNS & Neurological Disorders Drug Targets
Zeba MueedNitesh Kumar Poddar
September 16, 2020
Open Access

Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice

International Journal of Molecular Sciences
Alejandro R RodaSandra Villegas
August 26, 2020

Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016-2019)

Expert Opinion on Therapeutic Patents
Carlos Roca, Nuria E Campillo
June 27, 2020

An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Richard J CaselliGuojun Bu
June 26, 2020

Alzheimer's disease: unraveling APOE4 binding to amyloid-beta peptide and lipids with molecular dynamics and quantum mechanics

Journal of Biomolecular Structure & Dynamics
Jean-Numa Gillet
August 11, 2020
Review
Open Access

Beyond Host Defense: Deregulation of Drosophila Immunity and Age-Dependent Neurodegeneration

Frontiers in Immunology
Srishti Arora, Petros Ligoxygakis
July 18, 2020

Current Strategies and Novel Drug Approaches for Alzheimer Disease

CNS & Neurological Disorders Drug Targets
Roma GhaiGarima Kapoor
July 29, 2020
Preprint
Open Access

Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases

MedRxiv : the Preprint Server for Health Sciences
A. ThompsonSimon H Mead
August 11, 2020

Anti-Amyloid-β Protein agents for the treatment of Alzheimer's Disease: An update on emerging drugs

Expert Opinion on Emerging Drugs
Madia LozuponeFrancesco Panza
June 23, 2020
Review

Progress toward Alzheimer's disease treatment: Leveraging the Achilles' heel of Aβ oligomers?

Protein Science : a Publication of the Protein Society
Jacques FantiniNouara Yahi
June 11, 2020

Immunotherapy in progressive supranuclear palsy

Current Opinion in Neurology
Pavan A Vaswani, Abby L Olsen
July 15, 2020
Open Access

Gray matter changes related to microglial activation in Alzheimer's disease

Neurobiology of Aging
Nicolas NicastroJohn T O'Brien
July 14, 2020

Immunotherapy in progressive supranuclear palsy

Current Opinion in Neurology
Pavan A Vaswani, Abby L Olsen

Sign up to follow this feed and discover related papers.

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/tau-antibody-therapy-in-neurodegenerative/d55e613b-55f6-4469-92e8-bd3a5ea2c43f